{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T04:01:19Z","timestamp":1749096079437,"version":"3.41.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T00:00:00Z","timestamp":1468972800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schmerz"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s00482-016-0141-6","type":"journal-article","created":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T12:59:52Z","timestamp":1469019592000},"page":"519-525","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Interaktionen der Opioidanalgetika auf Ebene der Biotransformation","Interaction of opioid analgesics at the level of biotransformation"],"prefix":"10.1007","volume":"30","author":[{"given":"H.","family":"Petri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Grandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,20]]},"reference":[{"key":"141_CR1","unstructured":"BfArM (2013) Codein: Anwendungsbeschr\u00e4nkung bei der Schmerzbehandlung von Kindern. 22 August 2013"},{"issue":"3","key":"141_CR2","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0022-3565(25)20766-2","volume":"278","author":"Y Caraco","year":"1996","unstructured":"Caraco Y, Sheller Y, Wood AJ (1996) Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. J\u00a0Pharmacol Exp Ther 278(3):1165\u20131174","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"141_CR3","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/j.1365-2125.2012.04256.x","volume":"74","author":"JK Coller","year":"2012","unstructured":"Coller JK, Michalakas JR, James HM et al (2012) Inhibition of CYP2D6 mediated Tramadol O\u2011Demethylation in methadone but not buprenorphine maintenance patients. Br J Clin Pharmacol 74(5):835\u2013841","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"141_CR4","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/clpt.2013.254","volume":"95","author":"KR Crews","year":"2014","unstructured":"Crews KR, Gaedigk A, Dunnenberger HM et\u00a0al (2014) Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codein therapy:2014 update. Clin Pharmacol Ther 95(4):376\u2013382","journal-title":"Clin Pharmacol Ther"},{"key":"141_CR5","doi-asserted-by":"publisher","unstructured":"Cronnolly B, Pegrum H (2012) Fentanyl-clarithromycin interaction. BMJ Case Rep. doi: 10.1136\/bcr.02.2012.5936","DOI":"10.1136\/bcr.02.2012.5936"},{"key":"141_CR6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/ajh.21051","volume":"83","author":"DS Darbari","year":"2008","unstructured":"Darbari DS, van Schaik RH, Capparelli EV (2008) UGT2B7 promoter variant -840G\u3009A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am J Hematol 83:200\u2013202","journal-title":"Am J Hematol"},{"key":"141_CR7","unstructured":"Empfehlungen der S3-Leitlinie \u201eLangzeitanwendung von Opioiden bei nichttumorbedingten Schmerzen \u2013 \u201aLONTS\u2018\u201c. Aktueller Stand: 09\/2014, \u00dcberarbeitung 01\/2015"},{"key":"141_CR8","unstructured":"Fachinformation Actiq\u00ae. Stand: Februar 2015"},{"key":"141_CR9","unstructured":"Fachinformation Buprenaddict\u00ae Stand: Juli 2013"},{"key":"141_CR10","unstructured":"Fachinformation Durogesic\u00ae SMAT. Stand: Juli 2015"},{"key":"141_CR11","unstructured":"Fachinformation Gelonida\u00ae Stand: November 2014"},{"key":"141_CR12","unstructured":"Fachinformation Oxycodon-HCl AbZ. Stand: August 2015"},{"key":"141_CR13","unstructured":"Fachinformation Transtec PRO\u00ae. Stand: Juni 2014"},{"key":"141_CR14","unstructured":"Fachinformation Tybos\u00ae Stand: Mai 2015"},{"issue":"4","key":"141_CR15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ajim.21998","volume":"55","author":"GM Franklin","year":"2012","unstructured":"Franklin GM, Mai J, Turner J et\u00a0al (2012) Bending the prescription opioid dosing and mortality curves: impact of the Washington State opioid dosing guideline. Am J Ind Med 55(4):325\u2013331","journal-title":"Am J Ind Med"},{"key":"141_CR16","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1056\/NEJMoa041888","volume":"351","author":"Y Gasche","year":"2004","unstructured":"Gasche Y, Daali Y, Fathi M (2004) Codein intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351:2827\u20132831","journal-title":"N Engl J Med"},{"key":"141_CR17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s002100000266","volume":"362","author":"C Gillen","year":"2000","unstructured":"Gillen C, Haurand M, Kobelt DJ et al (2000) Affinity, potency and efficacy of tramadol and its metabolites at the cloned human \u03bc\u2011opioid receptor. Naunyn Schmiedeberg Arch Pharmacol 362:116\u2013121","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"141_CR18","unstructured":"Gilman AG, Goodman LS, Rall TW, Murad F (1985) Goodman and Gilman\u00b4s The Pharmacological Basis of Therapeutics. 7th Ed., MacMillan Publishing, New York, S.\u00a0506"},{"issue":"3","key":"141_CR19","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/cid\/cir799","volume":"54","author":"VA Gruber","year":"2012","unstructured":"Gruber VA, Rainey PM, Moody DE et al (2012) Interactions between Buprenorphine and the protease inhibitors Darunavir-Ritonavir and Fosamprenavir-Ritonavir. Clin Infect Dis 54(3):414\u2013423","journal-title":"Clin Infect Dis"},{"issue":"5","key":"141_CR20","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1365-2125.2012.04261.x","volume":"75","author":"B Gr\u00fcn","year":"2012","unstructured":"Gr\u00fcn B, Merkel U, Riedel KD et\u00a0al (2012) Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine. Br J Clin Pharmacol 75(5):854\u2013863","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"141_CR21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00228-008-0568-5","volume":"65","author":"NM Hagelberg","year":"2009","unstructured":"Hagelberg NM, Nieminen TH, Saari TI et\u00a0al (2009) Voriconazole drastically increases exposure to oral oxycodone. Eur J Clin Pharmacol 65(3):263\u2013271","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"141_CR22","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00228-006-0120-4","volume":"62","author":"P Hallberg","year":"2006","unstructured":"Hallberg P, Mart\u00e9n L, Wadelius M (2006) Possible fluconazole-fentanyl interaction \u2013 a case report. Eur J Clin Pharmacol 62(6):491\u2013492","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"141_CR23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2133\/dmpk.22.103","volume":"22","author":"Y Hara","year":"2007","unstructured":"Hara Y, Nakajima M, Miyamoto K et al (2007) Morphine glucuronosyltransferase activity in human liver microsomes is inhibited by a variety of drugs that are co-administered with morphine. Drug Metab Pharmacokinet 22(2):103\u2013112","journal-title":"Drug Metab Pharmacokinet"},{"issue":"8","key":"141_CR24","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/FPC.0b013e3283037fe4","volume":"18","author":"F Innocenti","year":"2008","unstructured":"Innocenti F, Liu W, Fackenthal D et al (2008) SNP discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene. Pharmacogenet Genomics 18(8):683\u2013697","journal-title":"Pharmacogenet Genomics"},{"issue":"9","key":"141_CR25","first-page":"583","volume":"32","author":"RP Kapil","year":"2012","unstructured":"Kapil RP, Cipriano A, Michels GH et al (2012) Effect of ketoconazole on the pharmacokinetic profile of buprenophine following administration of a once-weekly buprenorphine transdermal system. Clin Drug Investig 32(9):583\u2013592","journal-title":"Clin Drug Investig"},{"issue":"5","key":"141_CR26","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/med.20035","volume":"25","author":"GJ Kilpatrick","year":"2005","unstructured":"Kilpatrick GJ, Smith TW (2005) Morphine-6-glucuronide: actions and mechanisms. Med Res Rev 25(5):521\u2013544","journal-title":"Med Res Rev"},{"issue":"9536","key":"141_CR27","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0140-6736(06)69255-6","volume":"368","author":"G Koren","year":"2006","unstructured":"Koren G, Cairns J, Chitayat D et al (2006) Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 368(9536):704","journal-title":"Lancet"},{"issue":"9","key":"141_CR28","first-page":"1072","volume":"25","author":"RB Labroo","year":"1997","unstructured":"Labroo RB, Paine MF, Thummel KE et\u00a0al (1997) Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos 25(9):1072\u20131080","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"141_CR29","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.clpt.2004.11.002","volume":"77","author":"S Laugesen","year":"2005","unstructured":"Laugesen S, Enggaard TP, Pedersen RS (2005) Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O\u2011demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 77(4):312\u2013323","journal-title":"Clin Pharmacol Ther"},{"key":"141_CR30","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000326085","volume":"87","author":"W Leppert","year":"2011","unstructured":"Leppert W (2011) CYP2D6 in the metabolism of opioids for mild to moderate pain. Pharmacology 87:274\u2013285","journal-title":"Pharmacology"},{"issue":"6","key":"141_CR31","doi-asserted-by":"crossref","first-page":"494","DOI":"10.2174\/138920010791636211","volume":"11","author":"W Leppert","year":"2010","unstructured":"Leppert W (2010) Dihydrocodeine as an analgesic for the treatment of moderate to severe chronic pain. Curr Drug Metab 11(6):494\u2013506","journal-title":"Curr Drug Metab"},{"issue":"6","key":"141_CR32","doi-asserted-by":"crossref","first-page":"648.e9","DOI":"10.1016\/j.genhosppsych.2010.08.003","volume":"32","author":"TT Levin","year":"2010","unstructured":"Levin TT, Bakr MH, Nikolova T (2010) Case report: delirium due to a diltiazem-fentanyl CYP3A4 drug interaction. Gen Hosp Psychiatry 32(6):648.e9\u2013648.e10","journal-title":"Gen Hosp Psychiatry"},{"key":"141_CR33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s004820050142","volume":"12","author":"G Lindena","year":"1998","unstructured":"Lindena G, Arnau H, Liefhold J (1998) Hydromorphon \u2013 pharmakologische Eigenschaften und therapeutische Wirksamkeit. Schmerz 12:195\u2013204","journal-title":"Schmerz"},{"issue":"Suppl 5","key":"141_CR34","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jpainsymman.2005.01.004","volume":"29","author":"J L\u00f6tsch","year":"2005","unstructured":"L\u00f6tsch J (2005) Opioid metabolites. J\u00a0Pain Symptom Manage 29(Suppl 5):S10\u2013S24","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"141_CR35","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/bjaceaccp\/mkm033","volume":"7","author":"L Margetts","year":"2007","unstructured":"Margetts L, Sawyer R (2007) Transdermal drug delivery: principles and opioid therapy. Contin Educ Anaesth Crit Care Pain 7(5):171\u2013176","journal-title":"Contin Educ Anaesth Crit Care Pain"},{"issue":"2\u20133","key":"141_CR36","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.drugalcdep.2007.06.007","volume":"91","author":"EF McCance-Katz","year":"2007","unstructured":"McCance-Katz EF, Moody DE, Morse GD (2007) Interaction between Buprenorphine and Atazanavir or Atazanavir\/Ritonavir. Drug Alcohol Depend 91(2\u20133):269\u2013278","journal-title":"Drug Alcohol Depend"},{"issue":"Suppl 4","key":"141_CR37","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1086\/508187","volume":"43","author":"EF McCance-Katz","year":"2006","unstructured":"McCance-Katz EF, Moody DE, Morse GD et al (2006) Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis 43(Suppl 4):S224\u2013S234","journal-title":"Clin Infect Dis"},{"issue":"1","key":"141_CR38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1521-0391.2009.00006.x","volume":"19","author":"EF McCance-Katz","year":"2010","unstructured":"McCance-Katz EF, Moody DE, Morse GD et al (2010) Lack of clinically significant drug interactions between nevirapine and buprenorphine. Am J Addict 19(1):30\u201337","journal-title":"Am J Addict"},{"issue":"2\u20133","key":"141_CR39","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.drugalcdep.2011.04.013","volume":"118","author":"EF McCance-Katz","year":"2011","unstructured":"McCance-Katz EF, Moody DE, Prathikanti S et al (2011) Rifampin, but no rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug Alcohol Depend 118(2\u20133):326\u2013334","journal-title":"Drug Alcohol Depend"},{"key":"141_CR40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1086\/508188","volume":"43","author":"EF McCance-Katz","year":"2006","unstructured":"McCance-Katz EF, Moody DE, Smith PF (2006) Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir\/ritonavir, and ritonavir. Clin Infect Dis 43:235\u2013246","journal-title":"Clin Infect Dis"},{"key":"141_CR41","volume-title":"Buprenorphine: combatting drug abuse with a unique opioid","author":"HJ McQuay","year":"1986","unstructured":"McQuay HJ, Moore RA (1995) Buprenorphine kinetics in humans. In: Cowan A, Lewis JW (Hrsg) Buprenorphine: combatting drug abuse with a unique opioid. Wiley-Liss Inc., NewYork. S\u00a0137\u2013147"},{"issue":"3","key":"141_CR42","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0885-3924(02)00477-3","volume":"24","author":"S Mercadante","year":"2002","unstructured":"Mercadante S, Villari P, Ferrera P (2002) Itraconazole-fentanyl interaction in a cancer patient. J Pain Symptom Manage 24(3):284\u2013286","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"141_CR43","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jpainsymman.2006.08.005","volume":"33","author":"H Morii","year":"2007","unstructured":"Morii H, Chiba M, Konishi H, Endo Y et\u00a0al (2007) Failure of pain control using transdermal fentanyl during rifampicin treatment. J\u00a0Pain Symptom Manage 33(1):5\u20136","journal-title":"J Pain Symptom Manage"},{"key":"141_CR44","volume-title":"Mutschler Arzneimittelwirkungen","author":"E Mutschler","year":"2012","unstructured":"Mutschler E (2012) 2.4 Biotransformation. In: Mutschler Arzneimittelwirkungen, 10.\u00a0Aufl. Wissenschaftliche Verlagsgesellschaft, Stuttgart","edition":"10"},{"issue":"6","key":"141_CR45","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/ALN.0b013e31819faa54","volume":"110","author":"TH Nieminen","year":"2009","unstructured":"Nieminen TH, Hagelberg NM, Saari TI et\u00a0al (2009) Rifampicin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology 110(6):1371\u20131378","journal-title":"Anesthesiology"},{"issue":"8","key":"141_CR46","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ejpain.2009.12.007","volume":"14","author":"TH Nieminen","year":"2010","unstructured":"Nieminen TH, Hagelberg NM, Saari TI et\u00a0al (2010) St John\u2019s wort greatyl reduces the concentrations of oral oxycodone. Eur J Pain 14(8):854\u2013859","journal-title":"Eur J Pain"},{"key":"141_CR47","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/00000542-199909000-00020","volume":"91","author":"KT Olkkola","year":"1999","unstructured":"Olkkola KT, Palkama VJ, Neuvonen PJ (1999) Ritonavir\u2019s role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology 91:681\u2013685","journal-title":"Anesthesiology"},{"key":"141_CR48","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1533-2500.2010.00378.x","volume":"10","author":"J Pergolizzi","year":"2010","unstructured":"Pergolizzi J, Aloisi AM, Dahan A et\u00a0al (2010) Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract 10:428\u2013450","journal-title":"Pain Pract"},{"issue":"5","key":"141_CR49","first-page":"467","volume":"20","author":"JV Pergolizzi Jr","year":"2014","unstructured":"Pergolizzi JV Jr, Ma L, Foster DR et al (2014) The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients. J Manag Care Spec Pharm 20(5):467\u2013476","journal-title":"J Manag Care Spec Pharm"},{"key":"141_CR50","first-page":"283","volume":"35","author":"H Petri","year":"2014","unstructured":"Petri H (2014) Das Interaktionspotenzial hochpotenter Opioide. Krankenhauspharmazie 35:283\u2013285","journal-title":"Krankenhauspharmazie"},{"key":"141_CR51","first-page":"161","volume":"35","author":"H Petri","year":"2014","unstructured":"Petri H (2014) Das Interaktionspotenzial niederpotenter Opioide. Krankenhauspharmazie 35:161\u2013163","journal-title":"Krankenhauspharmazie"},{"key":"141_CR52","unstructured":"Prescribing information OXYCONTIN. Stand: August 2015"},{"key":"141_CR53","unstructured":"Prescribing information Tramadol. Stand: Mai 2010"},{"key":"141_CR54","first-page":"52","volume":"48","author":"K Reinecke","year":"2014","unstructured":"Reinecke K, B\u00f6hm R, Cascorbi I et\u00a0al (2014) Die Aufgaben der Transferasen. Dtsch Apoth Ztg 48:52\u201359","journal-title":"Dtsch Apoth Ztg"},{"issue":"4","key":"141_CR55","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00228-009-0775-8","volume":"66","author":"TI Saari","year":"2010","unstructured":"Saari TI, Gr\u00f6nlund J, Hagelberg NM et\u00a0al (2010) Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. Eur J Clin Pharmacol 66(4):387\u2013397","journal-title":"Eur J Clin Pharmacol"},{"key":"141_CR56","unstructured":"Schmerztherapie mit Opioiden (2011). Der Arzneimittelbrief 45:65\u201370"},{"issue":"1","key":"141_CR57","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.clpt.6100152","volume":"82","author":"UM Stamer","year":"2007","unstructured":"Stamer UM, Musshoff F, Kobilay M (2007) Concentrations of tramadol and O\u2011desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin Pharmacol Ther 82(1):41\u201347","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"141_CR58","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1345\/aph.1G370","volume":"39","author":"H Takane","year":"2005","unstructured":"Takane H, Nosaka A, Wakushima H et\u00a0al (2005) Rifampin reduces the analgesic effect of transdermal fentanyl. Ann Pharmacother 39(12):2139\u20132140","journal-title":"Ann Pharmacother"},{"issue":"3","key":"141_CR59","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF03190478","volume":"32","author":"R Terlinden","year":"2007","unstructured":"Terlinden R, Ossig J, Fliegert F et\u00a0al (2007) Absorption, metabolism, and excretion of 14C-labeled Tapentadol HCl in healthy male subjects. Eur J Drug Metab Pharmacokinet 32(3):163\u2013169","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"7","key":"141_CR60","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/FPC.0b013e32832e0eac","volume":"19","author":"CF Thorn","year":"2009","unstructured":"Thorn CF, Klein TE, Altman RB (2009) Codeine and morphine pathway. Pharmacogenet Genomics 19(7):556\u2013558","journal-title":"Pharmacogenet. Genomics"},{"issue":"8","key":"141_CR61","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00228-009-0640-9","volume":"65","author":"M Vevelstad","year":"2009","unstructured":"Vevelstad M, Pettersen S, Tallaksen C et al (2009) O\u2011demethylation of codeine to morphine inhibited by low-dose levomepromazine. Eur J Clin Pharmacol 65(8):795\u2013801","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"141_CR62","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1046\/j.1365-2125.1998.00727.x","volume":"45","author":"CH Wilder-Smith","year":"1998","unstructured":"Wilder-Smith CH, Hufschmid E, Thormann W (1998) The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizers. Br J Clin Pharmacol 45(6):575\u2013581","journal-title":"Br J Clin Pharmacol"}],"container-title":["Der Schmerz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-016-0141-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00482-016-0141-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-016-0141-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T03:06:27Z","timestamp":1749006387000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00482-016-0141-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,20]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["141"],"URL":"https:\/\/doi.org\/10.1007\/s00482-016-0141-6","relation":{},"ISSN":["0932-433X","1432-2129"],"issn-type":[{"type":"print","value":"0932-433X"},{"type":"electronic","value":"1432-2129"}],"subject":[],"published":{"date-parts":[[2016,7,20]]}}}